Capstone Therapeutics Corp. (NASDAQ:CAPS) Sees Significant Decline in Short Interest

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the recipient of a large drop in short interest in October. As of October 30th, there was short interest totaling 28,547 shares, a drop of 95.9% from the October 15th total of 696,378 shares. Based on an average daily trading volume, of 63,445 shares, the days-to-cover ratio is presently 0.4 days. Currently, 5.1% of the shares of the company are short sold.

Capstone Therapeutics Stock Performance

CAPS stock traded down $0.01 during midday trading on Tuesday, hitting $2.09. The company’s stock had a trading volume of 6,375 shares, compared to its average volume of 49,886. The company has a quick ratio of 0.39, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The stock’s 50-day moving average price is $3.96 and its 200 day moving average price is $10.36. Capstone Therapeutics has a 1 year low of $1.85 and a 1 year high of $34.80.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Capstone Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Capstone Therapeutics currently has a consensus rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.